A Multicenter, Randomized, Double-blind, Controlled Phase II Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin) for the Treatment of Knee Osteoarthritis
Latest Information Update: 02 Aug 2023
At a glance
- Drugs Allogeneic-adipose-derived-mesenchymal-stem-cell-therapy-AbelZeta-Pharma (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Cellular Biomedicine Group
Most Recent Events
- 30 Jul 2023 Status changed from active, no longer recruiting to completed.
- 08 May 2023 Planned End Date changed from 1 Jan 2022 to 1 Jun 2023.
- 08 May 2023 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2023.